Results 21 to 30 of about 304,324 (330)
Clinics, 2011 OBJECTIVE: The goal of the present study was to estimate the risk ratio of herpes zoster among systemic lupus erythematosus patients after disease onset compared with a cohort of patients without systemic lupus erythematosus over a three-year period ...
Hsin-Hua Chen +5 more
doaj +1 more source
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
New England Journal of Medicine, 2019 BACKGROUND Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a significant effect on the primary end point in a previous phase 3 trial.
E. Morand +10 more
semanticscholar +1 more source
Determinant Factors of Morbidity in Patients with Systemic Lupus Erythematosus
Acta Médica Portuguesa, 2017 Introduction: Severity in systemic lupus erythematosus may vary from mild to even fatal consequences. There are no biomarkers to predict the disease’s prognosis.
Margarida Jacinto +3 more
doaj +1 more source
Mapping Systemic Lupus Erythematosus heterogeneity at the single-cell level
Nature Immunology, 2020 Patients with systemic lupus erythematosus (SLE) display a complex blood transcriptome whose cellular origin is poorly resolved. Using single-cell RNA sequencing, we profiled ~276,000 peripheral blood mononuclear cells from 33 children with SLE with ...
Djamel Nehar-Belaid +24 more
semanticscholar +1 more source
Cutaneous Manifestations of “Lupus”: Systemic Lupus Erythematosus and Beyond
International Journal of Rheumatology, 2021 Lupus, Latin for “wolf,” is a term used to describe many dermatologic conditions, some of which are related to underlying systemic lupus erythematosus, while others are distinct disease processes.
Elizabeth E Cooper +2 more
semanticscholar +1 more source
Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus.
New England Journal of Medicine, 2020 Daratumumab, a human monoclonal antibody that targets CD38, depletes plasma cells and is approved for the treatment of multiple myeloma. Long-lived plasma cells are implicated in the pathogenesis of systemic lupus erythematosus because they secrete ...
L. Ostendorf +16 more
semanticscholar +1 more source
Toll-like receptor signalling in B cells during systemic lupus erythematosus
Nature Reviews Rheumatology, 2020 B lymphocytes have a central role in autoimmune diseases, which are often defined by specific autoantibody patterns and feature a loss of B cell tolerance.
S. Fillatreau, B. Manfroi, T. Dörner
semanticscholar +1 more source
DeckerMed Family Medicine, 2019 Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune illness characterized by autoantibodies directed at nuclear antigens that cause clinical and laboratory abnormalities, such as rash, arthritis, leukopenia and thrombocytopenia, alopecia, fever, nephritis, and neurologic disease.
Kyriakos A. Kirou, Michael D. Lockshin
openaire +1 more source
SAGE Open Medical Case Reports, 2020 Drug-induced lupus erythematosus has features distinct from primary systemic lupus erythematosus. It can occur with a wide variety of agents that result in the generation of anti-histone or other types of antibodies.
Umut Selamet +5 more
doaj +1 more source
Arthritis & Rheumatism, 1996 OBJECTIVE To develop and perform an initial validation of a damage index for systemic lupus erythematosus (SLE). METHODS A list of items considered to reflect damage in SLE was generated through a nominal group process. A consensus as to which items to
D. Gladman +21 more
semanticscholar +1 more source